DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows:

• 33^rd Annual Roth Conference
  Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
  Company conference participation date: March 15^th, 2021

• Oppenheimer’s 31^st Annual Healthcare Conference
  Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
  Company conference participation date: March 16^th, 2021

• Maxim’s Emerging Growth Conference
  Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
  Company conference participation date: March 17^th, 2021

For more information or to schedule a one-on-one meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005912/en/

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Source: DiaMedica Therapeutics Inc.

Released March 8, 2021